41 completed, 11 unknown, 7 recruiting, 3 enrolling by invitation. 22 Phase 2, 18 Phase 3, 12 Not applicable, 12 Phase 4, 8 Phase 1.
Follow Cabergoline: new trials by email Literature Review of Cabergoline trials Research Report on Cabergoline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline Viaca, Sildenafil 50 mg, Cabergoline 0.5 MG - Erectile Dysfunctions, Healthy Volunteer | Phase 1 | Not yet recruiting | Yanping Kong | 30 | 2026-08-01 | 2026-07-28 |
| A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss Cabergoline - Lactation Suppressed | Phase 2 | Withdrawn | Stanford University | 2026-07-01 | 2026-07-17 | |
| Combination Osilodrostat and Cabergoline in Cushing's Disease osilodrostat, osilodrostat and cabergoline - Cushing Disease Due to Increased ACTH Secretion | Phase 4 | Enrolling by invitation | University of Basrah | 50 | 2026-05-11 | 2026-05-22 |
| Carbergoline for Antipsychotic Induced Hyperprolactinemia. Cabergoline (Dopamine Agonist), Placebo - Scizophrenia | Phase 4 | Not yet recruiting | Zealand University Hospital | 146 | 2026-05-01 | 2026-02-04 |
| Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms Cabergoline, Placebo - Pregnancy, Abortion | Phase 2 | Recruiting | Jefferson Drapkin | 348 | 2026-03-16 | 2026-09-17 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Safety and Potency of a High Cabergoline Dosage in Microprolactinomas Cabergoline - Prolactinoma, Prolactin Excess | Phase 3 | Recruiting | University of Sao Paulo General Hospital | 70 | 2026-03-04 | 2026-03-13 |
| Cabergoline for Episodic Migraine Cabergoline 0.5 MG, Placebo, Cabergoline 1 MG - Migraine | Phase 2 | Recruiting | Aarhus University Hospital | 150 | 2025-11-12 | 2025-11-18 |
| Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment Cabergoline (Dopamine Agonist) - Prolactinoma | Phase 4 | Recruiting | University Hospital, Basel, Switzerland | 60 | 2025-09-16 | 2025-09-23 |
| A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets Cabergoline tablets, Bromocriptine mesylate tablets - Hyperprolactinemia | Phase 3 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 382 | 2025-09-12 | 2025-10-02 |
| Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome Coasting, Cabergoline - Gynecologic Disease | Phase 2 | Recruiting | Tanta University | 150 | 2025-06-30 | 2026-03-13 |
| A Study on Bioequivalence of Cabergoline Tablets in Human Body Cabergoline tablets test formulation, Cabergoline tablets reference formulation - Hyperprolactinemia | Phase 1 | Active not recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 72 | 2025-06-30 | 2025-11-17 |
| Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS Letrozole 0.5mg, Cabergoline 0.5 mg - PCOS | Not applicable | Recruiting | Mst.Sumyara Khatun | 72 | 2025-02-07 | 2025-12-16 |
| Cabergoline in the Management of Nonfunctioning Pituitary Adenoma Cabergoline 0.5 MG - Pituitary Adenoma, MRI | Phase 4 | Enrolling by invitation | National Taiwan University Hospital | 30 | 2024-05-20 | 2025-06-24 |
| Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss Cabergoline 1 MG, Placebo - Lactation Suppressed | Phase 2 | Completed | Stanford University | 69 | 2024-02-07 | 2025-10-03 |
| Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion Cabergoline, Placebo - Lactation Suppressed, Second Trimester Abortion | Phase 4 | Completed | Northwestern University | 15 | 2023-12-18 | 2026-10-15 |
| Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction Letrozole tablets - PCOS (Polycystic Ovary Syndrome) | Not applicable | Completed | Al-Azhar University | 100 | 2023-01-10 | 2025-09-11 |
| Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin Calcium Gluconate - Ovarian Hyperstimulation Syndrome | Not applicable | Completed | Minia University | 180 | 2022-10-01 | 2025-01-07 |
| Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS Metformin Hydrochloride 500 MG, Cabergoline 0.5 MG, Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG - Polycystic Ovary Syndrome | Phase 2 | Completed | Al-Rasheed University College | 75 | 2022-09-21 | 2023-08-08 |
| Cabergoline as a Preventive Treatment for Chronic Migraine Cabergoline 0.5 MG, Placebo - Migraine | Not applicable | Completed | University of Aarhus | 36 | 2022-09-05 | 2024-02-26 |
Showing 20 of 70. Sign in to see all of them.
Ovarian Hyperstimulation Syndrome (7) · Pituitary Neoplasms (7) · Hyperprolactinemia (6) · Infertility (6) · Prolactinoma (6) · Acromegaly (4) · Parkinson Disease (4) · Pituitary ACTH Hypersecretion (4) · Endometriosis (3) · Polycystic Ovary Syndrome (3) · Breast Feeding (2) · Cocaine-Related Disorders (2) · Diabetes Mellitus (2) · Hyperemia (2) · Infertility, Female (2)
Benha University (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · Stanford University (3) · Aljazeera Hospital (2) · Boston Children's Hospital (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Northwestern University (2) · Par Pharmaceutical, Inc. (2) · University of Aarhus (2) · University of Sao Paulo General Hospital (2) · Woman's Health University Hospital, Egypt (2) · Aarhus University Hospital (1) · Al-Azhar University (1) · Al-Rasheed University College (1)
Egypt (14) · United States (14) · Brazil (7) · Germany (7) · Italy (7) · India (5) · Spain (5) · Canada (4) · Denmark (4) · Poland (4) · Switzerland (4) · Argentina (3) · France (3) · Mexico (3) · Portugal (3)
Eric Masson, Pharm.D. (2) · Usama M Fouda, M.D,PhD (2) · Abbas A Mansour (1) · Abla Mohamed Ebeid, Ph D (1) · Ahmed M Kamel, MD (1) · Ahmed Maged, MD (1) · Anil Bhansali, MD DM (1) · Annamaria AL Colao, Prof. (1) · Antonio Pellicer, MD (1) · Ashraf Moini, MD (1) · Ashraf N Elmantwe, MD (1) · Ashu Rastogi, MD (1)
PMID 33851429, PMID 10753124, PMID 11880025, PMID 12390688, PMID 12934784, PMID 14627787, PMID 15081648, PMID 15272916, PMID 15817912, PMID 16148287, PMID 16181243, PMID 16267335, PMID 16705142, PMID 17202453, PMID 17202454, PMID 18682513, PMID 19439914, PMID 21296991, PMID 21553090, PMID 22231013, PMID 23347435, PMID 23824978, PMID 23932181, PMID 25418156, PMID 27150495, PMID 27184139, PMID 30540568, PMID 31523136, PMID 34934987, PMID 35954244, PMID 37486652, PMID 37827268, PMID 37863161, PMID 37876540, PMID 40168298, PMID 41221041, PMID 41538804, PMID 9467544
2025 (2), 2005 (1)